Overcome Adherence Challenges in Oncology with spencer®

Introduction

Cancer is the second leading cause of death in the United States,¹ and an estimated 2 million people will be diagnosed with various types of cancer in 2023 alone.² Historically, treatment has included IV chemotherapy and radiation, but now oral, self-administered medications are becoming more common as the number of oral chemotherapeutic drugs has increased ten-fold in the last 20 years.

Oncology medication adherence is a critical factor influencing treatment outcomes, quality of life, and overall patient experience. Patients diagnosed with cancer often face complex medication regimens, including multiple drugs with varying dosing schedules and potential side effects. Non-adherence to these treatments can lead to serious consequences, such as disease progression, increased risk of complications, and higher healthcare costs. Addressing the challenge of oncology medication adherence requires innovative solutions that prioritize patient needs and improve treatment outcomes.

Managing medication as an oncology patient is extremely difficult, “Cancer treatment usually involves taking a lot of medications. In addition to drugs directly related to treatment, cancer patients may also be taking medicines for pain, nausea, low blood counts and other treatment- or cancer- related symptoms. Some patients may take up to 20 pills a day.”³ Adherence rates reported in the literature are highly variable, particularly as cancer type, patient sampling and adherence measurement methods are not standardized. As one example, patients taking oral oncolytic therapies for multiple myeloma only achieve 80% adherence at a rate of 68%, with 36% ultimately discontinuing treatment.⁴ A comprehensive review by Greer, et al. noted that adherence rates to oral oncology therapies can be as low as 43%.⁵ A study of adherence to imatinib in chronic myelogenous leukemia patients demonstrated that adherence greater than 90% led to a major molecular response rate (MMR) of 94.5%, while MMR was less than 30% when adherence less than 90%.⁶ Despite the variability, it is clear that adherence and persistence on oral oncology therapies is problematic which can lead to disease progression and poor health outcomes.

The Complexities of Oncology Medication Adherence

Oncology treatment regimens frequently involve a combination of oral and intravenous medications, each with specific dosing instructions and administration guidelines. Patients must carefully manage their medications while coping with the physical and emotional challenges of cancer. Factors contributing to oncology medication adherence challenges include:

Complex treatment plans: Multiple medications, varying dosages, and treatment cycles can be overwhelming.
Side effects: Adverse reactions to cancer treatments can lead to medication discontinuation.
Patient forgetfulness: Busy schedules and cognitive impairments associated with cancer can contribute to missed doses.
Financial barriers: High medication costs can hinder patient access and adherence.

The Impact of Non-Adherence on Oncology Patients

Non-adherence to oncology medications has far-reaching consequences for patients. Research indicates that suboptimal adherence is linked to:

Increased risk of disease progression: Patients who do not adhere to their treatment plans may experience faster disease progression and poorer overall survival rates.
Higher hospitalization rates: Non-adherence can lead to treatment-related complications, requiring hospitalization.
Reduced quality of life: Adverse side effects and treatment interruptions can significantly impact patients’ well-being.
Increased healthcare costs: Hospitalizations, emergency room visits, and additional medications due to treatment failures contribute to higher healthcare expenditures.

The Role of Smart Technology in Improving Oncology Medication Adherence

Digital therapeutics, such as spencer®, offer promising solutions to address the challenges of oncology medication adherence. These innovative platforms leverage technology to deliver evidence-based interventions and improve patient outcomes. Key features of digital therapeutics for oncology medication adherence include:

Automated medication dispensing: Ensures accurate and timely medication delivery.
Real-time adherence monitoring: Tracks medication intake and provides insights for healthcare providers.
Patient education and support: Offers educational resources and personalized guidance.
Remote monitoring of patient status: Enables early detection of potential issues and timely interventions.

Introducing spencer®: A Patient-Centric Solution

spencer is a game-changer in medication management. Designed with patient input, this innovative device simplifies the medication-taking process through user-friendly features:

Automated dispensing: Medications are dispensed at the correct time, eliminating the risk of missed doses.
Visual and audible alerts: Gentle reminders ensure patients stay on track.
Patient engagement: Interactive features encourage patient participation in their care.
Data collection: Real-time data on medication adherence provides valuable insights for healthcare providers.

By combining these elements, spencer empowers patients to take control of their treatment and improves overall medication adherence.

The Role of spencer® in Optimizing Oncology Medication Adherence

spencer is designed to address the multifaceted challenges of oncology medication adherence. By combining advanced technology with a patient-centric approach, spencer offers a comprehensive solution to improve treatment outcomes. Key features include:

Automated medication dispensing: Ensures accurate and timely medication delivery, reducing the risk of missed doses.
Real-time adherence monitoring: Provides valuable data on medication intake patterns, enabling healthcare providers to identify potential issues early.
Patient engagement tools: Incorporates educational resources, reminders, and support features to enhance patient empowerment.
Integration with healthcare systems: Facilitates seamless communication between patients, caregivers, and healthcare providers.

By leveraging these features, spencer has the potential to significantly improve oncology medication adherence and enhance the overall patient experience.

Conclusion

Optimizing oncology medication adherence is essential for improving patient outcomes and reducing healthcare costs. By addressing the complex challenges faced by patients and healthcare providers, spencer® offers a promising approach to enhancing treatment efficacy and patient satisfaction. Continued research and development in this area are crucial to advancing the field of oncology care.

Next Steps for Getting Started

Remember, spencer® is more than a medication dispenser; it’s a comprehensive solution designed to enhance oncology medication adherence. By providing timely reminders, facilitating communication with healthcare providers, and offering discreet medication management, spencer empowers patients to take control of their treatment journey.

Are you ready to transform the way you engage with your oncology patients? By prioritizing patient needs and implementing innovative solutions like spencer, you can improve adherence, enhance patient outcomes, and strengthen your brand’s reputation. Contact us today to learn how spencer can elevate your patient engagement strategy.

References:

ACS Medical Content and News Staff. Risk of Dying from Cancer Continues to Drop at an Accelerated Pace. https://www.cancer.org/research/acs-research-news/facts-and-figures-2022.html
Cancer Stat Facts: Common Cancer Sites. Accessed November 20, 2023. https://seer.cancer.gov/statfacts/html/common.html
Managing Medications During Cancer Treatment. Accessed November 20, 2023. https://www.mdanderson.org/patients-family/diagnosis-treatment/emotional-physical-effects/managing-medications.html#:~:text=Cancer%20treatment%20usually%20involves%20taking,to%2020%20pills%20a%20day.
Naser AY, Ofori-Asenso R, Awawdeh S Al, Qadus S, Alwafi H, Liew D. Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2022;22(10):760-773. doi:10.1016/J.CLML.2022.05.003 https://pubmed.ncbi.nlm.nih.gov/35764491/
Greer J, Amoyal N, Nisotel L, et al. A Systematic Review of Adherence to Oral Antineoplastic Therapies. The Oncologist. Published online March 21, 2016. Accessed November 20, 2023. https://pubmed.ncbi.nlm.nih.gov/26921292/
Marin D, Bazeos A, Mahon FX, et al. Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib. Journal of Clinical Oncology . Published online May 10, 2010. Accessed November 20, 2023. https://pubmed.ncbi.nlm.nih.gov/20385986/